Home / Business and Economy / Vertex Pharmaceuticals Reports Strong Q2 2026
Vertex Pharmaceuticals Reports Strong Q2 2026
4 Aug
Summary
- Vertex's Q2 2026 revenue grew 12% to $3.3 billion.
- Full-year revenue guidance raised to $13.1-$13.2 billion.
- Cystic fibrosis franchise revenue increased 11% year over year.
Vertex Pharmaceuticals achieved a significant 12% year-over-year revenue increase in the second quarter of 2026, reaching $3.3 billion. The company has subsequently raised its full-year revenue forecast to between $13.1 billion and $13.2 billion. This strong performance is primarily attributed to the continued success of its cystic fibrosis (CF) franchise.
The global revenue for the CF segment grew by 11% compared to the previous year. Key drivers include the uptake of ALYFTEX, which surpassed $1 billion in the first half of 2026, and sustained contributions from TRIKAFTA. The company is also advancing regulatory submissions for ALYFTEX in younger children and expects data on its next-generation CFTR modulator, VX-828, in the latter half of 2026.
